**Manuscript ID: HMS-A-23-00003**

**Clinical Management, Treatment Pattern and Medications of COVID-19 in Bangladesh: A Randomized Cross-Sectional Prescriptive Study**

Abstract

Before introducing of COVID-19 vaccines the management of COVID-19 has mainly been performed by a blend of repurposing of drugs and adopting the traditional practice. At present, COVID-19 is managed by vaccine immunization in addition to repurposing of drugs and traditional practice. The present study aimed to identify the treatment pattern of COVID-19 along with the traditional practices followed in Bangladesh and justify their purposes of use. For this purpose, a randomized cross-sectional prescriptive study was conducted among COVID-19 survivors who received treatment from hospitals or staying at home to collect their prescriptions, other medical records, and interview on to discuss on different aspects of their disease conditions and treatment. The patients’ prescriptions and interview reports were used to identify mostly used classes of drugs, their frequency and other traditional practices followed by the patients suggested by doctors. These prescriptions were then analyzed to establish a treatment pattern followed by the common people of Bangladesh. The data were collected from a total of 184 participants (age between 18 years to 80 years old) of COVID-survivors of both sexes residing in different locations of Dhaka city in Bangladesh during 10 March 2021 to 30 July 2021. Among the 184 participants, 123 were from non-hospitalized and 61 from hospitalized patients. The numbers of male COVID-19 patients were higher than that of female. We found that COVID-19 patients were treated with several classes of medications. The major classes of medicaments used were antiviral drugs (Ivermectin, Remdisivir, Favipiravir), antibiotics (Azithromycin, Doxycycline, Amoxicillin+Clavulanic acid, Cefuroxime, Cefixime, Moxifloxacin, Gemifloxacin, Levofloxacin, Meropenem), anticoagulants (Rivaroxaban, Enoxaparin, Betrixaban), and nutritional supplements (Vitamin C, Vitamin D, Vitamin B complex, Zinc, Multivitamin, Daflon, Pancreatin, Calcium+Amino acid). Traditional healing practices were also followed by patients at home including inhalation of water vapor, consumption of spiced tea, physical exercises, and gurgling with hot water with verbal suggestion or without the suggestion of the physicians. The treatment pattern of COVID-19 was mostly symptomatic. Although the treatment pattern and the type of repurposing drugs were mostly followed WHO and country’s guidelines, the frequent use of antibiotics and corticosteroids were not in compliance with the above guidelines. The COVID-19 treatment pattern practiced in Bangladesh was mostly found to be symptomatic which was aligned with the guidelines of WHO and drug administration of Bangladesh except the use irrational and frequent use of antibiotics and corticosteroids.

Keywords: COVID-19, SARS-CoV-2, COVID-19 treatment, Repurposing of drugs, Antibiotics, Steroids, Nutraceuticals, Traditional treatment method, Traditional medicine, Bangladesh

# Introduction

# Coronavirus, known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), is a deadly virus that turned out to be a devastating outbreak all over the world. It becomes highlighted on 31st December 2019 as the China health authority alerted WHO (world health organization) about a new type of severe pneumonia of very different etiology in the main city of Hubei Province of China, Wuhan. The cases had been reported since December 8, 2019, and many patients worked at or lived around the local Huanan Seafood Wholesale Market although other early cases had no exposure to this market (1). On January 7, a novel corona virus, originally abbreviated as 2019-nCoV by WHO, was identified from the throat swab sample of patient (2). This pathogen was later renamed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group (3), and the disease was named coronavirus disease 2019 (COVID-19) by the WHO.

# As of 30 January 2020, 7736 confirmed and 12,167 suspected cases had been reported in China and 82 confirmed cases had been detected in 18 other countries (4). In the same day, WHO declared the SARS-CoV-2 outbreak as a Public Health Emergency of International Concern (PHEIC) (4). As of today (13 December 2021), coronavirus has spread in 222 countries and territories with 269,468,311 confirmed cases of COVID-19 and 5,304,248 deaths (5). Bangladesh is not also an exception. On 8 March 2020, the first case of COVID-19 was confirmed in Bangladesh. Between 8 March and 15 May 2020, according to the Directorate General of Health Services (DGHS) on behalf of the Ministry of Health in Bangladesh, there were 20,065 COVID-19 confirmed cases by rt-PCR including 298 related death cases where the case fatality rate (CFR) was 1.48%, highest confirm case was identified on 15 May which was 1202 and highest death was figured out on 13 May, 2020 (6). The pandemic of COVID-19 has badly affected in Bangladesh likewise other countries. The government is trying its best to tackle this devastating situation. According to WHO Bangladesh report, there have been 1,579,710 confirmed cases of COVID-19 with 28,031 deaths in Bangladesh between 03 January 2020 to 13 December 2021 (7).

# Meanwhile vaccines from various sources have been introduced in Bangladesh and the number of COVID-19 cases and death rate have also been reduced significantly. Yet, parallel treatment for COVID-19 infected patients are practiced with the repurposing of drugs and other treatment mentioned earlier. However, diversity of SARS-CoV-2 and frequent change of new variants is a great challenge towards the effectiveness of vaccines [8]. Furthermore, adequate production, allocation, storage conditions and affordable prices for purchasing are some of the major challenges in the way of sufficient production, supply, and chain management and to ensure its efficacy and safety (9-12).

# Prior to sufficient availability and supply of COVID-19 vaccines, the only treatment options for COVID-19 patients was repurposing of drugs. The recovery rate of COVID-19 patients could be increased by applying several evidence-based repurposed antiviral drugs that slow down the replication of SARS-CoV-2 and/or decrease disease symptoms (13). According to NIH guidelines, the recommended repurposing drugs that can be used in COVID-19 patients are Remdisivir, Dexamethasone (alternatively prednisolone or methylprednisolone could be used) and Baricitinib, used evaluating the conditions of the patients. WHO recommended differently towards the treatment procedure. Remdisivir, hydroxychloroquine, azithromycin were recommended for the COVID-19 patients. Later on, Remdisivir and hydroxychloroquine were withdrawn from the suggested guideline, the later was suspected to cause various heart diseases (14,15). According to NIH guidelines, Remdisivir can be considered administering to inpatient hospital with constant monitoring in severe cases, though renal insufficiency is a major point of contraindication in this usage (16). The treatment pattern in Bangladesh is represented in the website of the directorate general of health services (DGHS), Government of the Peoples’ Republic of Bangladesh, where several drugs are recommended for the treatment purposes of COVID-19 patients. Based on the severity and symptoms, the drugs such as, Paracetamol, Chloroquine, Remdisivir, Corticosteroids, Favipiravir, Tocilizumab, Interleukin, etc. were recommended in this guideline (16, 17). In Bangladesh, the prevention and treatment of COVID-19 is managed by a blend of repurposing of drugs, immunization, oxygen and ventilation support and by applying traditional practice and intake of vitamins and other supplements. However, enough research has not been conducted so far to present a clear picture on the clinical practice, treatment pattern and medications used for the management of COVID-19 patients in Bangladesh as well as nobody has justified those practice with the standard practice and guidelines given by WHO and/or followed by other developed countries of the world. That’s why the present study was carried out to investigate the medicaments of COVID-19 patients in Bangladesh including repurposing and conventional medicines and justify the rationality of the medicines used based on diagnosis, symptoms and underlying co morbidities as well as to compare the WHO and DGHS guidelines.

# Materials and Methods

## Study subjects, consent, and ethical aspect

## The study participants were representative (184 COVID-19 patients of age 18-80 years) of COVID-19 survivals of Bangladesh. The study subjects (COVID-19 patients) were randomly selected from different COVID-19 hospitals, clinics as well as who received treatment staying at home.

The consent of the patients was obtained before conducting the study. The objectives, significance, risk and benefits, etc. of the study were explained to the patients before getting their consent for participation in the study. The COVID-19 survivals who could provide written prescription of physicians and agreed to participate willingly were included in the study.

## An ethical approval for the study protocol was obtained from the institutional review board (IRB) for human ethics of the State University of Bangladesh before conducting the study (Protocol approval no: 2020-12-15/SUB/H-ERC/0002).

## Collection of data

## After getting informed consent, the patients were asked to provide a photocopy or picture of their prescriptions along with other medical reports (if available). Additionally the patients were also asked about the medicines they have taken (according to or without prescriptions provided by health care practitioners), the dose and dosage regimen of the medicines, and the management policies followed by them throughout the treatment period. Besides, the severity of their diseases, complications, and other questions relating to COVID-19 and it’s treatment were asked for better clarification and evaluation of the justification of their prescriptions. The prescriptions were collected physically as well as through online platform (email, messenger, whatsapp, etc.). Interview/discussion with the patients were performed face to face as well as by phone call or audio/video call using messenger, whatsapp, imo, viber or online zoom meeting.

## The data were collected from prescriptions and discussion with 184 COVID-19 survivors (hospitalized and non-hospitalized). The data collection period was from 10 March 2021 to 30 July 2021. The name and personal information of the patients were kept confidential and the patients were coded with patients ID starting from P-01 to P-184. Among the study subjects, 61 patients were hospitalized and received treatment in hospital, and 123 patients received COVID-19 treatments staying at home as per the prescriptions of physicians. The collected data of medicaments and other traditional practice which were advised to follow by the physicians as a part of their treatment procedure have been summarized in Table 1 and Table 2.

## Results

## Demographic characteristics of the patients

## Among total 184 patients, 61.4% is male and 38.6% is female (Figure 1a). In case of 61 hospitalized patients, male patients are more (55.7%) than female ones (44.3%); and among the 123 non-hospitalized patients, male patients were 64.2% and female patients were 35.8% (Figure 1a).

## We have divided the patients in two groups according to age. Among 184 patients, 59.8% patient is below 40years and 40.2% is above 40 years. When we consider only hospitalized patients, 49.2% of them is below 40 years and 50.8% is above that year. For non-hospitalized patients, 65% is below 40 years and 35% is above that age. These data have been summarized in Figure 1b.

**3.2 Clinical management of COVID-19 patients in Bangladesh**

**3.2.1 COVID-19 confirmation test:** All the patients tested positive in the confirmed COVID test by various recognized national and private organizations solely designated for tests.

**3.2.2 Biochemical tests/ analysis:** Several biochemical tests were suggested like CBC with ESR, serum ferritin, D-Dimer, Chest X-ray and HRCT which was acknowledged by patients while conversation and observation of treatment records.

**3.2.3 Physical observation:** Symptoms of the patients were noted and listed in the table included as an attachment. Common symptoms include fever, headache, body ache, chest tightness, cough, sore throat breathing difficulty etc. Comorbidities for instance hypertension, diabetes, insomnia, kidney disease etc. were also identified through diagnosis.

**3.2.4 Oxygen saturation:** Typical problem arisen from COVID pneumonia was hypoxia which means low oxygen saturation level in blood. It is one of the major complications of COVID-19 that the oxygen saturation drops all of a sudden in COVID patients. So, every patient was suggested to monitor his/her oxygen saturation level on a regular basis regardless of staying at home or hospital.

**3.2.5 Ventilation:** Severe patients were transferred to ICU and under ventilation. Those who were unable to breathe were under artificial methods to assist breathing (ventilator).

**3.2.6 Treatment:** Various drugs were prescribed both for symptomatic and prophylactic treatment to the patients according to their age, symptoms and stage of infection.

**3.3 Treatment procedure of COVID-19 patients in Bangladesh**

Moving forward towards the treatment procedure, there are several classes of drugs that were used named antiviral, antibiotic, antipyretic, antitussive, corticosteroid, mucolytes, anxiolytic, anticoagulant, antihistamine, vitamin and mineral supplements, and bronchodilators. Occasionally monoclonal antibody, antidiabetic, antihypertensive, antiprotozoal and cholesterol-lowering agents were also prescribed summarized in Table 1.

**3.3.1 Categories of drugs used for COVID-19 patients’ treatment**

**3.3.1.1 Repurposing of antiviral drugs:**

Among the antiviral drugs, Ivermectin, Remdisivir and Favipiravir were used. The topmost and only antiviral drug prescribed in non-hospitalized patients is Ivermectin having a frequency of 56 prescriptions out of 122 (46%) (Fig. 2a). In the case of hospitalized patients, Ivermectin and Remdisivir were in 17 and 25 prescriptions respectively (28% and 41% respectively) whereas Favipiravir use was very low consuming 1 prescription (2%) (Fig. 2b).

**3.3.1.2 Repurposing of antibiotics:**

In case of antibiotics, mostly used drugs were Azithromycin (class: Macrolide), Doxycycline (class: tetracycline), Amoxicillin and Clavulanic acid combination (class: Penicillin), Cefuroxime, Cefixime (class: cephalosporin), Moxifloxacin, Gemifloxacin and Levofloxacin (Fluoroquinolone) and Meropenem (class: carbapenem). Considering the use of antibiotics, Azithromycin was prevalent (28%, 17 prescriptions), followed by Penicillin and Fluoroquinolone (23%, 14 prescriptions), Meropenem (16%, 10 prescriptions), Doxycycline (11%, 7 prescriptions) and Cephalosporin (7%, 4 prescriptions) - all for hospitalized patients (Fig. 2b). For non-hospitalized ones, Azithromycin was mostly prescribed covering 46 prescriptions (37%), while Fluoroquinolone, Doxycycline, Cephalosporin and Penicillin were in 5, 38, 8 and 2 prescriptions respectively (4%, 28%, 7% and 2% respectively) (Fig. 2a).

**3.3.1.3 Antihistamines:**

Mostly used antihistamine was Fexofenadine, occasionally Rupatadine and Ebastin were prescribed. Antihistamines were prescribed in 21 cases (34%) of hospitalized patients (Fig. 2b). One of the highest prescribed drug classes are Antihistamine (46%) found in 56 prescriptions of non-hospitalized patients (Fig. 2a).

**3.3.1.4 Anticoagulants:**

The main anticoagulant drugs used were Rivaroxaban and Enoxaparin, Betrixaban was also given in few cases. In the case of hospitalized patients, anticoagulants were used most frequently covering 34 prescriptions among 61 prescriptions (56%) (Fig. 2b). For non-hospitalized ones, anticoagulants were prescribed in 20 cases (16%) (Fig. 2a).

**3.3.1.5 Bronchodilators:**

Montelukast was used in almost all cases except a few, other bronchodilators include Salbutamol, Salmetrelol and Fluticasone combination, Bumetanide, Budesonide and Doxophylline. Montelukast was one of the most popular drugs being in 32 prescriptions (52%) whereas other Bronchodilator use was in 23 cases (38%) in hospitalized patients (Fig. 2b). Bronchodilators were in 24 prescriptions (20%) of non-hospitalized patients. Montelukast was prescribed alongside in 46 prescriptions (37%) (Fig. 2a).

**3.3.1.6 Immunosuppressants:**

The only prescribed immunosuppressant corticosteroid was Dexamethasone. Dexamethasone was suggested for 20 cases (33%) in hospitalized cases (Fig. 2b). For non-hospitalized ones (Fig. 2a), the prescription frequency for this drug is much less, that is 1 prescription (1%).

**3.3.1.7 Antitussive agents:**

Dextromethorphan, Butamirate citrate and its combination with Phenylephrine and Tripolidin and Bromohexine HCl were the drugs used as an antitussive. For hospitalized patients, antitussives are prescribed for 13 cases (21%) and for the non-hospitalized group, Antitussives were prescribed in 16 prescriptions (13%).

**3.3.1.8 Supplements:**

Common nutritional supplements include Vitamin C and D, Zinc, Combination of Zinc and Vitamin B, Multivitamin, Daflon, Pancreatin and Calcium-Amino acid combination. Vitamin supplements were present in all the prescriptions of hospitalized patients (Fig. 2b), where Vitamin C was in 31 prescriptions (51%), Vitamin D in 23 prescriptions (38%), Zinc and zinc-Vitamin B combination in 35 prescriptions (57%), Multivitamin in 4 Prescriptions (7%) and Pancreation, Daflon and Amino acid- Calcium combination, all these three have frequency of 1 prescription (2% each). One of the most popular sections of the drug in non-hospitalized cases is a nutritional supplement (Fig. 2a). In this section, vitamin C is the most popular one consuming 73 prescriptions (59%), other supplements are Multivitamin, Amino acid-Calcium combination, Zinc and Zinc-Vitamin B combination and Vitamin D which were in 4, 2, 57 and 33 prescriptions respectively (3%, 2%, 46% and 27% respectively).

**3.3.1.9 Paracetamol:**

An only antipyretic drug used where fever existed was Paracetamol. It was found in 35 prescriptions (Fig. 2b) of hospitalized patients (57%) and for non-hospitalized ones (Fig. 2a) the number was 94 prescriptions (76%).

**3.3.1.10 Drugs used for the treatment of comorbidities of COVID-19 patients or to support other symptoms:**

Tocilizumab, Baricitinib and Lubiprostone were used in severe COVID-19 patients in recent prescriptions of the hospitalized segment as immunomodulators. Clonazepam, Bromazepam, Flupentixol-Malitracen and Diltiazem were used as anxiolytics and PPI used were Esomeprazole and famotidine. For antiemetic and mucolytes the drugs suggested were Domperidone and N-acetyl cysteine respectively. Ezetimib, Rosuvastatin and Atorvastatin were popular cholesterol-lowering agents, Sitagliptin, Lenagliptin, Metformin and Insulin were prescribed as antidiabetic drugs. Mostly used antihypertensive agents are Verapamil, Amlodipine, Amlodipine-Olmesartan combination, Losartan and Bisprolol and antiprotozoal is Metronidazole. Topiramate was also in the list.

Other drugs for hospitalized patients (Fig. 2b) include mucolytes for 3 cases (5%), PPI for 13 case (21%) and anxiolytics for 7 cases (11%). Antihypertensives, Cholesterol-lowering agents and immunomodulators were only in 12, 3 and 9 prescriptions respectively (20%, 5% and 15% respectively). Antidiabetic drugs were used in the frequency of 2 cases for Lenagliptin and Metformin (3%), 6 cases for insulin (10%) and 1 case for Sitagliptin (2%). Topiramate (for severe headache), Domperidone (for vomiting tendency) and aspirin (blood-thinning agent) were found in 1 prescription each (2%). Other classes of drugs were not much frequent in non-hospitalized patients (Fig. 2a). PPI was prescribed in 12 prescriptions (10%), anxiolytics, antihypertensives, mucolytes, domperidone and metronidazole were prescribed in 3, 5, 1, 4 and 5 prescriptions respectively (2%, 4%, 1%, 3%, 4%). All of them were prescribed according to the comorbidities or symptoms of the patient.

**3.3.1.11 Traditional home remedies:**

Several traditional home remedies are seen to be suggested by the healthcare practitioners in this COVID-19 disease summarized in Table 1 and table 2. Almost all of the patients who were being treated from staying at home were suggested to inhale water vapour thrice a day. It is well accepted now that this method has reduced the severity of illness in a good number of cases while the mechanism is still unclear (17). Other suggestions include tea consumption which is made with cinnamon, clove, cardamom, ginger, black pepper, honey etc., having lots of citrus fruits, gurgle with hot water and some exercises were also suggested to eradicate difficulty breathing and chest tightness.

Patients being hospitalized were more severe in condition and are unable to practice the above-mentioned methods. They have frequently undergone nebulization, oxygen supplement, ventilation in more severe cases and were under constant monitoring of oxygen saturation.

1. **Discussion**

From the treatment pattern, we can summarize that most of the drugs are being used to cure the secondary effects of COVID-19. While some antiviral drugs are used to fight against the prevailing virus, antibiotics are used to prevent the secondary lung infection caused by bacteria. Despite being an antiparasitic, ivermectin is used for antiviral purposes in COVID-19 patients. Ivermectin is used with a variety of doses depending on the weight of the patient but in the case of COVID-19 patients mostly used dose is 18 mg regardless of body weight. There is no confirmed mechanism of this drug to explain its effect in COVID-19 yet it is used as it has plummeted the mortality rate significantly in Bangladesh. Ivermectin proved its antiviral effect against COVID-19 pathogen in vitro but it is still under clinical trial (18-19).

Most of the other classes of drugs like antitussive, antihistamine, bronchodilators etc. are used according to the symptoms of the patients (Table 3). For example, patients having cough as a symptom was prescribed with antitussive (Dextromethorphan, Bromhexine etc.) and those who suffered from chest tightness were given bronchodilators (Salbutamol, Doxophylline, Montelukast etc.). Antihistamines were prescribed for common cold symptoms like runny nose etc. Patients bearing fever, body ache and headache were prescribed with Paracetamol for its analgesic and antipyretic role.

SARS-Cov-2 has shown two types of properties, it can be classified as symptomatic and asymptomatic having a different degree of infectiousness (20). It is assumed that those having strong immunity are a victim of asymptomatic COVID-19 and it is an immunity which forbids the disease becoming severe. Multiple cases supported this fact and as a result, immune boosting supplements became a part of COVID-19 treatment. Several supplements especially Zinc and its combination with Vitamin B complex, Vitamin C, Vitamin D are the most popular ones. Apart from the mentioned ones, Daflon, multivitamin, calcium (both alone and in combination with amino acid) and mucolytes are prescribed in some cases.

Post-COVID heart attack and coagulation have taken a vicious shape in the patients (21). To avoid this complication, anticoagulant rivaroxaban and enoxaparin were prescribed in almost all the cases; betrixaban was used instead in the case of only one patient. Other classes of drugs were antihypertensive, antidiabetic, anxiolytic drugs which were prescribed particularly in the case of patients diagnosed with hypertension, diabetes mellitus and sleeping disturbances respectively. The only steroid drug used was Dexamethasone and it was used in case of sustained fever. Domperidone was prescribed for patients having vomiting tendency and Metronidazole was present if the patient had diarrhea as a symptom. Some drugs from the class statin were used for obese patients.

Immunomodulators are used in severe COVID-19 patients. Baricitinib was used from the early phase. It has shown the antiviral property by inducing interferon-mediated immune response (21). Lubiprostone was used for one case for a similar indication. Recent use of Tocilizumab is being seen in severe COVID-19 patients. As pneumonia is the most serious complication of COVID-19 infection, Tocilizumab interacts with the pro-inflammatory interleukin-6 that eventually suppresses the pneumonitis produced by the virus afterwards (22).

Along with the medicines, doctors also suggested following some traditional practices to the patients who were at home (23). These include vapors inhaling, masala tea and citrus fruit consumption, monitoring oxygen saturation and exercise to clear the airway. Among these, steam in-halation was the most effective way to improve the condition. Sometimes a number of traditional plants are suggested to add to the hot water and then inhale the steam. Some phytochemicals of these suggested plants are proven to be effective to help people combating the SARS-CoV-2 virus (24). For hospitalized patients, who were under ICU observation were mostly supported with oxy-gen and oxygen saturation was monitored regularly. Severe patients were under ventilation. Patients with less severe complications were monitored under the COVID unit with symptomatic treatments.

One most serious problem detected from the treatment pattern is irrational use of dexamethasone in patients having comorbidities like hypertension, diabetes and hypercholesterolemia. Dexamethasone is contraindicated in these patients, but the survey shows that it was prescribed even if the patients were diagnosed with the mentioned comorbidities.

If we compare this treatment pattern with WHO and DGHS guidelines, we will find several deviations from the international and national ones. According to WHO guidelines (25), symptomatic treatment was recommended in mild, moderate and severe patients but the antibiotic is not suggested unless there is strong evidence for secondary bacterial infection. If we evaluate DGHS instructions (https://dghs.gov.bd/index.php/bd/publication/guideline), we will find out that along with symptomatic treatment low molecular weight Heparin (Enoxaparin/Rivaroxaban) is also recommended for thromboprophylaxis. Remdisivir is recommended in severe cases and must be given under the observation of a clinician. Both the guidelines suggested Dexamethasone in critical COVID patients.

The antibiotic guideline is the same in DGHS as in the WHO guideline. The deviation we can observe most is the use of antibiotics in COVID patients. In all the patients (mild, moderate and severe) antibiotics were prescribed regardless of secondary bacterial infections. This could be alarming as random use of antibiotics can lead to antibiotic resistance. Another difference is seen in the Dexamethasone prescription, as patients who were not critical but only had long term fever were prescribed with this drug.

The affected and mortality rate in Bangladesh are relatively low till now compared to other countries for several reasons. As the use of drugs is not restricted in Bangladesh, multiple drugs are being used which eventually has become beneficial. Also people in Bangladesh are exposed to lots of microorganisms and environmental pollutions which made the herd immunity to be strong. The people may be immunized against other viruses like COVID-19, which served positively in this pandemic.

It must be said that the continuous evolving new evidences, exclusive large sample data, geo-graphical location, and type of studies (observational, retrospective, small-sized clinical trials, or independent case series) are some limitations in this study. So, we feel the need for a multi-centered, large sample-sized, randomized, placebo-controlled trial on appropriate COVID-19 patients to reach a proper conclusion on the selection of right choice of treatment, management and medication.

**5. Conclusion**

In reality, the continuing COVID-19 pandemic is a matter of national and international health concern. That is why, within a short period of time, vaccine against the virus has been applied to a number of countries, but observation of prevention capacity and safety level are being required many more times. This survey tries to investigate the rational use of repurposing and conventional medicaments against COVID-19 patients in Bangladesh depending on their diagnosis, symptoms and underlying comorbidities as well as to compare the guidelines between WHO and DGHS. It is true that a number of deviations of treatment patterns from the international and national guide-lines have been found out in this survey. In the basis of practical cases, according to COVID-19 prescription data, the most usable drugs (antiviral, antitussive, antihistamine, bronchodilators, anticoagulant, Immunomodulators, several supplements, some traditional practices, etc.) showed a significant number of patient’s improvements regarding COVID-19 related complication as well as reduced the number of mortality rate though in some cases irrationally used of dexamethasone were also present. As a developing country to compete with the devastating condition of COVID-19, Bangladesh should focus on scaling up the current clinical management, treatment pattern and type of medications to fight against the COVID-19.

## Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Author Contributions Statement

# Conceptualization: MMRS and TJ; collection of prescription and interview of the patients: TJ, SA, MJH, MLN, SA; writing - original draft preparation: TJ, SA, MJH, MLN; writing-review, and editing: MMRS, MJH, AF, LCM,YMA-W, INM; supervision: MMRS. All authors have read and agreed to publish the manuscript.

# Funding

# This research received no external funding.

# Acknowledgments

# Authors would like to deliver their thanks to all frontline fighters of COVID-19 (medical Doctors, Pharmacists, Nurses and others healthcare workers) who are delivering services to the patients taking the risk of infections as well as psychological stress at the pandemic of COVID-19; in addition delightful thanks to all the participants who contributed to the studies with their prescriptions and other information.

# Data Availability Statement

Data relevant to the study is already included to the article or attached in the supplements. Raw data will be provided on reasonable request upon contacting with the corresponding author.

# References

1. Lu, H.; Stratton, C. W.; Tang, Y. W. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol (2020) 92:4, p. 401-402. Doi: https://dx.doi.org/10.1002%2Fjmv.25678
2. Hui, D. S.; Azhar, E. I.; Madani, T. A.; Ntoumi, F.; Kock, R.; Dar, O.; Ippolito, G.; Mchugh, T. D.; Memish, Z. A.; Drosten, C. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J Infect Dis (2020) 91, p. 264-266. Doi: https://doi.org/10.1016/j.ijid.2020.01.009
3. Gorbalenya, A. E.; Baker, S. C.; Baric, R.; Groot, R. J. d.; Drosten, C.; Gulyaeva, A. A.; Haagmans, B. L.; Lauber, C.; Leontovich, A. M.; Neuman, B. W. Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Study Group. Biorxiv [preprint] (2020). Doi: https://doi.org/10.1101/2020.02.07.937862
4. Burki, T.K. Coronavirus in China. Lancet Respir Med (2020) 8:3, p. 238. Doi: https://dx.doi.org/10.1016%2FS2213-2600(20)30056-4
5. WHO Coronavirus (COVID-19) Dashboard (2021) https://covid19.who.int/ [Accessed on 14 December 2021]
6. Hossain, I.; Mullick, A. R.; Khan, M. H.; Ahmad, S. A.; Rahman, M. S.; Aktaruzzaman, M. Epidemiology of Coronavirus Disease: Past, Present, Future Prospects and Its Journey Towards Bangladesh. Clin Epidemiol (2020) 25:6, p. 2517-2528.
7. COVID-19: Bangladesh situation (2021). https://covid19.who.int/region/searo/country/bd (accessed on 13 December 2021)
8. Bari S, Hossain J, Akhter S, Emran TB. Delta variant and black fungal invasion: A bidirectional assault might worsen the massive second/third stream of COVID-19 outbreak in South-Asia. Med Public Health. (2021) 19:107347. Doi: https://doi.org/10.1016/j.jemep.2021.100722
9. Polack, F. P.; Thomas, S. J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J. L.; Marc, G. P.; Moreira, E. D.; Zerbini, C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med (2020) 383: 2603-2615. Doi: 10.1056/NEJMoa2034577
10. Folegatti, P. M.; Ewer, K. J.; Aley, P. K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E. A. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet (2020) 396: 10249, p. 467-478. Doi: https://doi.org/10.1016/S0140-6736(20)31604-4
11. Wouters, O. J.; Shadlen, K. C.; Salcher-Konrad, M.; Pollard, A. J.; Larson, H. J.; Teerawattananon, Y.; Jit, M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet (2021) 397:10278, p. 1023-1034. Doi: https://doi.org/10.1016/S0140-6736(21)00306-8
12. Hossen, M. S.; Barek, M. A.; Jahan, N.; Safiqul Islam, M. A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Compr Clin Med (2020) 2, p. 1777-1789. Doi: https://doi.org/10.1007/s42399-020-00485-9
13. Hossain M, Jannat T, Brishty SR, Roy U, Mitra S, Rafi M, Islam M, Nesa M, Emran TB. Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. Biologics (2021) 1:2, p. 252-84. Doi: https://doi.org/10.3390/biologics1020016
14. Lepere, P.; Escarguel, B.; Yolartiran, S.; Escarguel, C. Can Early Home administration of Azithromycin with Zinc Help Prevent Severe COVID-19 Disease Progression and Long-COVID? J Exp Pathol (2021) 2:2, p. 75-89.
15. Alam, S.; Sarker, M.; Rahman, M.; Afrin, S.; Richi, F. T.; Zhao, C.; Zhou, J.-R.; Mohamed, I. N. Traditional Herbal Medicines, Bioactive Metabolites, and Plant Products Against COVID-19: Update on Clinical Trials and Mechanism of Actions. Front Pharmacol (2021) 12:671498, p. 1248. Doi: https://doi.org/10.3389/fphar.2021.671498
16. NIH COVID-19 Treatment Guidelines (2021) https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/remdesivir. [Accessed on April 01, 2021]
17. Rahman, M. S.; Rahman, T. Risks of Simultaneous Coinfection of Dengue and COVID-19 in Bangladesh: Challenges and Recommendations. DSAHMJ (2020) 2:4, p. 137-139. Doi: https://dx.doi.org/10.2991/dsahmj.k.201124.001
18. Pawar, D.; Adsul, B.; Bhalla, R.; Chavhan, S.; Bhonsale, D.; Bhalla, S.; Mahajan, H. Use of steam as adjuvant-treatment in covid-19 patients: an observational study. Ind Med Gaz (2020) 1-2.
19. Chaccour, C.; Hammann, F.; Ramón-García, S.; Rabinovich, N. R. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg (2020) 102:6, p. 1156-1157. Doi: https://dx.doi.org/10.4269%2Fajtmh.20-0271
20. Caly, L.; Druce, J. D.; Catton, M. G.; Jans, D. A.; Wagstaff, K. M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res (2020) 178: 104787. Doi: https://doi.org/10.1016/j.antiviral.2020.104787
21. Sayampanathan, A. A.; Heng, C. S.; Pin, P. H.; Pang, J.; Leong, T. Y.; Lee, V. J. Infectivity of asymptomatic versus symptomatic COVID-19. Lancet (2021) 397:10269, p. 93-94. Doi: https://doi.org/10.1016/S0140-6736(20)32651-9
22. Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol (2020) 5:7, p. 802-810. Doi: 10.1001/jamacardio.2020.0950
23. Favalli, E. G.; Biggioggero, M.; Maioli, G.; Caporali, R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis (2020) 20:9, p. 1012-1013. Doi: https://doi.org/10.1016/S1473-3099(20)30262-0
24. Perrone, F.; Piccirillo, M. C.; Ascierto, P. A.; Salvarani, C.; Parrella, R.; Marata, A. M.; Popoli, P.; Ferraris, L.; Marrocco-Trischitta, M. M.; Ripamonti, D. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med (2020) 18:405, p. 1-11. Doi: https://doi.org/10.1186/s12967-020-02573-9
25. Alam, S.; Kamal, T. B.; Sarker, M. M. R.; Zhou, J.-R.; Rahman, S. A.; Mohamed, I. N. Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in (2021) Front Pharmacol 2021, 12:659577. Doi: https://dx.doi.org/10.3389%2Ffphar.2021.659577



**Figure 1.** Demographic characteristics of patients; (A) Percentage of male and female patients according to their sex in case of COVID-19 patients.; (B) Percentage of male and female patients according to their age group (below and above 40 years) in case of COVID-19 patients.





**Figure 2.** Frequency of drugs prescribed; (A) Frequency of different drug classes prescribed for the COVID-19 patients received treatment from home; (B) Frequency of different drug classes prescribed for the COVID-19 patients admitted to hospital and under specialists’ observation due to severe condition.